To date, no controlled trials have studied whether ⍺1-AR antagonism improves clinical outcomes in patients with lower respiratory tract infection (pneumonia, acute respiratory distress syndrome, or COVID-19). The gene discussed is AR; the disease is susceptibility to pneumonia measurement.